scispace - formally typeset
L

Lijun Wu

Researcher at Millennium Pharmaceuticals

Publications -  51
Citations -  14542

Lijun Wu is an academic researcher from Millennium Pharmaceuticals. The author has contributed to research in topics: Chemokine receptor & CC chemokine receptors. The author has an hindex of 36, co-authored 48 publications receiving 14193 citations. Previous affiliations of Lijun Wu include Stanford University & Harvard University.

Papers
More filters
Journal ArticleDOI

The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates

TL;DR: The ability of various members of the chemokine receptor family to support the early stages of HIV-1 infection helps to explain viral tropism and beta-chemokine inhibition of primary HIV- 1 isolates.
Journal ArticleDOI

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5

TL;DR: It is suggested that HIV-1 attachment to CD4 creates a high-affinity binding site for CCR-5, leading to membrane fusion and virus entry.
Journal ArticleDOI

The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes

TL;DR: The largely reciprocal expression of CXCR4 and CCR5 among peripheral blood T cells implies distinct susceptibility of T cell subsets to viral entry by T cell line- Tropic versus macrophage-tropic strains during the course of HIV infection.
Journal ArticleDOI

The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells

TL;DR: The results suggest that CCR4 and TARC are important in the recognition of skin vasculature by circulating T cells and in directing lymphocytes that are involved in systemic as opposed to intestinal immunity to their target tissues.
Journal ArticleDOI

CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro

TL;DR: Anti-CCR5 mAbs were poor inhibitors of chemokine binding, indicating that HIV-1 and ligands bind to separate, but overlapping regions of CCR5, and demonstrate the feasibility of blocking macrophage-tropic HIV- 1 entry into cells with an anti-CCr5 reagent.